Table 1.
Drugs designed to target IL-6 signaling.
| Drug | Activity |
|---|---|
| Ruxolitinib | Inhibitor of JAK1 and JAK287 |
| AZD1480 | Inhibitor of JAK1 and JAK288 |
| BMS-911543 | Selective JAK2 inhibitor89 |
| STAT3 decoy | Highly specific inhibitor of STAT385, 86 |
| Tocilizumab | Humanized anti-human IL-6R antibody28 |
| Siltuximab | Anti-IL-6 antibody91, 92 |
| G-quartet Oligodeoxynucleotides | Disrupts STAT3 DNA binding96 |
| mAb 1339 | Anti-IL-6 monoclonal antibody97 |
| BE-8 | Anti-IL-6 monoclonal antibody90 |
| Eriocalyxin B (EB) | Inhibits constitutive and IL-6-mediated STAT3 activation98 |
| Curcumin (diferuloylmethane) Curcumin analog (H-4073) |
Inhibits STAT3 phosphorylation and nuclear translocation80 Inhibits STAT3 phosphorylation and chemoresistance81 |
| Azelastine | Inhibits IL-6-mediated STAT3 activation76 |
| Guanidinoquinazolines, Triazolothiadiazines, Amino alcohols, and Oxazole-piperazine singleton | Inhibits IL-6-mediated STAT3 activation77 |